12:00 AM
 | 
Sep 07, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bexxar tositumomab regulatory update

The FDA informed CLTR and partner SmithKline Beecham (Philadelphia, Penn.) that their BLA for Bexxar to treat relapsed or refractory low-grade or...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >